Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?

Dig Liver Dis. 2021 Mar;53(3):383-384. doi: 10.1016/j.dld.2020.12.123. Epub 2021 Jan 20.

Authors

Francesco Angelico¹, Francesco Baratta², Daniele Pastori³, Maria Del Ben³

Affiliations

¹ Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.
² Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy. Electronic address: [email protected].
³ Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy.

PMID: 33483258
DOI: 10.1016/j.dld.2020.12.123

No abstract available

Publication types

Letter
Comment

MeSH terms

Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / etiology
Heart Disease Risk Factors
Humans
Liver Cirrhosis
Non-alcoholic Fatty Liver Disease*
Risk Factors